Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Future directions in right heart disease

Future directions in right heart disease

Treating the right ventricle itself, rather than only the circulation loading it.

Right heart and pulmonary circulation

RV-directed therapy

Current treatment for pulmonary vascular disease acts on the pulmonary circulation; the right ventricle improves if afterload falls. Whether the failing RV can be treated directly — targeting its fibrosis, metabolism or contractility — is the central open question, and no RV-specific therapy is established.

Antiproliferative and disease-modifying approaches

The shift in pulmonary arterial hypertension from vasodilator therapy toward agents targeting vascular remodelling represents a move from symptomatic to disease-modifying treatment. Whether remodelling can be reversed rather than slowed, and how early intervention must occur, are the questions following from it.

Earlier detection

RV failure presents late because adaptation masks it. Work on earlier markers — strain imaging, biomarkers, exercise haemodynamics — aims at identifying the transition from adaptive to maladaptive remodelling while it may still be reversible.

The neglected populations

Right heart involvement in heart failure with preserved ejection fraction, in chronic lung disease and in congenital heart disease is common and under-studied relative to its prevalence. Group 2 and group 3 pulmonary hypertension have far less trial evidence than group 1, and treatments established in group 1 have not generally transferred — a point where extrapolation has caused harm.

Methodological direction

Outcome measures are contested. Six-minute walk distance has limited responsiveness and uncertain patient relevance; composite endpoints including clinical worsening, and patient-reported outcomes, are increasingly used. Core outcome set work would help comparability across trials.

In short

What to take from this.

  • No RV-specific therapy is established — current treatment acts on afterload.
  • Do not extrapolate group 1 PAH treatments to groups 2 and 3.
  • Six-minute walk distance is a weak primary endpoint.

Sources

  • Established pulmonary hypertension treatment literature
  • Outcome measure literature in pulmonary vascular disease

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.